A Mab A Case Study In Bioprocess Development

Identifying the physical, chemical, biological, or microbiological properties that must remain within defined limits to ensure safety and efficacy.

[Quality Target Product Profile (QTPP)] │ ▼ [Critical Quality Attributes (CQAs)] │ ▼ [Risk Assessment / FMEA] │ ▼ [Critical Process Parameters (CPPs)] │ ▼ [Design Space] │ ▼ [Control Strategy] From Target Profile to Control Strategy

As mAb titers from upstream processes have increased (from ~1 g/L a decade ago to over 10 g/L today), the downstream process has often become the bottleneck. New technologies and strategies are emerging to address this. One innovative approach, described by Bio-Rad, involves using a two-step purification process that replaces the two traditional polishing columns with a single strong anion exchange-hydrophobic interaction chromatography (AEX-HIC) mixed-mode resin, reducing costs and increasing yield. Similarly, membrane chromatography is being validated as a high-productivity alternative to resin-packed columns for polishing, enabling faster processing. The A-Mab case study itself provides a hypothetical yet thorough risk assessment for each of these downstream unit operations, using leached Protein A, DNA, and other impurities as examples of attributes to be controlled. A Mab A Case Study In Bioprocess Development

This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety.

The next step in the bioprocess development of A Mab was the development of a scalable fermentation process. A Mab was produced in a fed-batch mode using a 50 L bioreactor. The fermentation process involved a combination of batch and fed-batch phases, with a cell growth phase followed by a production phase. This case study demonstrates that a modern mAb

The A-Mab case study is a hypothetical, humanized IgG1 monoclonal antibody designed to maximize clinical performance while minimizing undesirable product quality attributes. Rather than offering a simple recipe, the study provides a comprehensive framework for process development, emphasizing a shift from a purely empirical, "quality-by-testing" approach to a proactive, science-driven, "quality-by-design" (QbD) mindset.

The platform approach (CHO + Protein A + CEX/AEX + VF) reduced development time to from clone to phase 1 material. mixing speed) and outputs (e.g.

The study utilizes a Design of Experiments (DoE) approach at a 2L scale to define a "scale-independent" design space. This ensures that parameters like dissolved oxygen (set at ~60%) and nutrient feeding strategies remain effective at commercial scales. 3. Downstream Process Development a-mab-case-study-version.pdf - ISPE

Once the CQAs are identified, the next step is to develop a deep mechanistic understanding of how manufacturing process parameters affect these CQAs. This involves systematic experimentation, often using Design of Experiments (DoE) methodologies, to map the relationship between inputs (e.g., bioreactor pH, temperature, mixing speed) and outputs (e.g., cell growth, titer, glycosylation profile).

The upstream process for Mab-X begins with a Chinese Hamster Ovary (CHO) cell line engineered to secrete the antibody. The case study focuses on three key challenges: